Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients

Chin Chou Wang; Chia Cheng Tseng; Huang Chih Chang; Kuo Tung Huang; Wen Feng Fang; Yu Mu Chen; Cheng Ta Yang; Chang Chun Hsiao; Meng Chih Lin; Chi Kung Ho; Hon Kan Yip

doi:10.18632/oncotarget.18372

Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients

Chin Chou Wang, Chia Cheng Tseng, Huang Chih Chang, Kuo Tung Huang, Wen Feng Fang, Yu Mu Chen, Cheng Ta Yang, Chang Chun Hsiao, Meng Chih Lin, Chi Kung Ho, Hon Kan Yip^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

25 Scopus citations

Abstract

We investigated whether circulating microparticles (MPs) could serve as prognostic biomarkers in non-small cell lung cancer (NSCLC) patients. We enrolled 25 control subjects and 136 NSCLC patients categorized into disease-progression (DP, n=42) and disease-control (DC, n=94) groups. Flow cytometric analysis showed that levels of four types of circulating microparticles (EDAc-MPs, EDAp-MPs, PDAc-MPs and PDAp-MPs) were higher in the study patients than the control subjects (P < 0.04). DP patients showed poor initially performance status and more non-adenocarcinomas than DC patients. DC patients showed more EGFR mutations and poorer performance to targeted therapy than DP patients (P < 0.01). Three months after therapy, the levels of all four types of circulating MPs were lower in DC than DP patients (P < 0.02), and were comparable to the levels in control subjects. In addition, the levels of circulating MPs after 3 months accurately predicted one-year prognostic outcomes (P < 0.05). This study showed that circulating MPs are valuable prognostic biomarkers in advanced NSCLC patients.

Original language	English
Pages (from-to)	75952-75967
Number of pages	16
Journal	Oncotarget
Volume	8
Issue number	44
DOIs	https://doi.org/10.18632/oncotarget.18372
State	Published - 2017

Bibliographical note

Publisher Copyright:
© Wang et al.

Keywords

Advanced non-small cell lung cancer
Disease control
Disease progression
Microparticles

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.18632/oncotarget.18372

Cite this

@article{a8b25c3518424e1f94c70624436cf4d6,

title = "Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients",

abstract = "We investigated whether circulating microparticles (MPs) could serve as prognostic biomarkers in non-small cell lung cancer (NSCLC) patients. We enrolled 25 control subjects and 136 NSCLC patients categorized into disease-progression (DP, n=42) and disease-control (DC, n=94) groups. Flow cytometric analysis showed that levels of four types of circulating microparticles (EDAc-MPs, EDAp-MPs, PDAc-MPs and PDAp-MPs) were higher in the study patients than the control subjects (P < 0.04). DP patients showed poor initially performance status and more non-adenocarcinomas than DC patients. DC patients showed more EGFR mutations and poorer performance to targeted therapy than DP patients (P < 0.01). Three months after therapy, the levels of all four types of circulating MPs were lower in DC than DP patients (P < 0.02), and were comparable to the levels in control subjects. In addition, the levels of circulating MPs after 3 months accurately predicted one-year prognostic outcomes (P < 0.05). This study showed that circulating MPs are valuable prognostic biomarkers in advanced NSCLC patients.",

keywords = "Advanced non-small cell lung cancer, Disease control, Disease progression, Microparticles",

author = "Wang, {Chin Chou} and Tseng, {Chia Cheng} and Chang, {Huang Chih} and Huang, {Kuo Tung} and Fang, {Wen Feng} and Chen, {Yu Mu} and Yang, {Cheng Ta} and Hsiao, {Chang Chun} and Lin, {Meng Chih} and Ho, {Chi Kung} and Yip, {Hon Kan}",

note = "Publisher Copyright: {\textcopyright} Wang et al.",

year = "2017",

doi = "10.18632/oncotarget.18372",

language = "英语",

volume = "8",

pages = "75952--75967",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "44",

}

TY - JOUR

T1 - Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients

AU - Wang, Chin Chou

AU - Tseng, Chia Cheng

AU - Chang, Huang Chih

AU - Huang, Kuo Tung

AU - Fang, Wen Feng

AU - Chen, Yu Mu

AU - Yang, Cheng Ta

AU - Hsiao, Chang Chun

AU - Lin, Meng Chih

AU - Ho, Chi Kung

AU - Yip, Hon Kan

PY - 2017

Y1 - 2017

N2 - We investigated whether circulating microparticles (MPs) could serve as prognostic biomarkers in non-small cell lung cancer (NSCLC) patients. We enrolled 25 control subjects and 136 NSCLC patients categorized into disease-progression (DP, n=42) and disease-control (DC, n=94) groups. Flow cytometric analysis showed that levels of four types of circulating microparticles (EDAc-MPs, EDAp-MPs, PDAc-MPs and PDAp-MPs) were higher in the study patients than the control subjects (P < 0.04). DP patients showed poor initially performance status and more non-adenocarcinomas than DC patients. DC patients showed more EGFR mutations and poorer performance to targeted therapy than DP patients (P < 0.01). Three months after therapy, the levels of all four types of circulating MPs were lower in DC than DP patients (P < 0.02), and were comparable to the levels in control subjects. In addition, the levels of circulating MPs after 3 months accurately predicted one-year prognostic outcomes (P < 0.05). This study showed that circulating MPs are valuable prognostic biomarkers in advanced NSCLC patients.

AB - We investigated whether circulating microparticles (MPs) could serve as prognostic biomarkers in non-small cell lung cancer (NSCLC) patients. We enrolled 25 control subjects and 136 NSCLC patients categorized into disease-progression (DP, n=42) and disease-control (DC, n=94) groups. Flow cytometric analysis showed that levels of four types of circulating microparticles (EDAc-MPs, EDAp-MPs, PDAc-MPs and PDAp-MPs) were higher in the study patients than the control subjects (P < 0.04). DP patients showed poor initially performance status and more non-adenocarcinomas than DC patients. DC patients showed more EGFR mutations and poorer performance to targeted therapy than DP patients (P < 0.01). Three months after therapy, the levels of all four types of circulating MPs were lower in DC than DP patients (P < 0.02), and were comparable to the levels in control subjects. In addition, the levels of circulating MPs after 3 months accurately predicted one-year prognostic outcomes (P < 0.05). This study showed that circulating MPs are valuable prognostic biomarkers in advanced NSCLC patients.

KW - Advanced non-small cell lung cancer

KW - Disease control

KW - Disease progression

KW - Microparticles

UR - http://www.scopus.com/inward/record.url?scp=85030314812&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18372

DO - 10.18632/oncotarget.18372

M3 - 文章

C2 - 29100283

AN - SCOPUS:85030314812

SN - 1949-2553

VL - 8

SP - 75952

EP - 75967

JO - Oncotarget

JF - Oncotarget

IS - 44

ER -

Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this